Johnson & Johnson Offers $5.5 Billion to Settle Talc Lawsuits

Johnson & Johnson has agreed to a $5.5 billion settlement to resolve the remaining lawsuits that claim its talc products caused ovarian cancer. The pharmaceutical giant has been engaged in litigation over these claims for over a decade. This proposed settlement is contingent upon at least 95% of the remaining claimants agreeing to participate. Previously, a $9 billion settlement proposed by the company's subsidiary, Red River Talc, was denied by a U.S. bankruptcy court judge last year, which would have been one of the largest mass tort settlements in history. Johnson & Johnson opted not to appeal that ruling, choosing instead to proceed with litigation.

In a recent development, a federal judge ordered plaintiffs in the talc claims against Johnson & Johnson to demonstrate why their remaining pending claims should not be dismissed, following their witnesses' inability to establish a direct link between the company's talc product and cancer. Erik Haas, worldwide vice president of litigation for Johnson & Johnson, stated in a prepared statement on Monday that the court's order placed plaintiffs in an "untenable position of having to present specific causation evidence to maintain their claims that does not exist." This indicates a significant legal hurdle for the plaintiffs.

Under the terms of the settlement proposed this week, Johnson & Johnson is slated to make an initial payment of no more than $3 billion in the upcoming year. The company will not be required to make any further payments until 2028. Haas further commented that while the company was confident in its ability to prevail in further litigation, having succeeded in the "vast majority of cases tried to date," this resolution will allow the company to move past this issue and concentrate on its core mission of developing life-saving medicines and devices. Johnson & Johnson has already settled approximately 95% of lawsuits related to mesothelioma, a cancer affecting the tissues surrounding organs such as the lungs and heart, along with all state consumer protection claims and disputes with talc suppliers.

Following the announcement of the proposed settlement, shares of Johnson & Johnson, headquartered in New Brunswick, New Jersey, saw an increase of over 2% in pre-market trading on Tuesday. The company's consistent success in defending against talc-related claims in court has been a key factor in its strategy, with this settlement aiming to provide a definitive resolution to the long-standing legal challenges. The $5.5 billion figure represents a significant financial commitment, underscoring the scale of the litigation and the company's desire for closure.